一种新型黑色素瘤的蛋白质预后模型

A Novel Protein Prognostic Model for Melanoma

黑色素瘤是一种最具侵袭性和最难以治疗的癌症之一,目前黑色素瘤的治疗主要是使用靶向药物和免疫治疗药物。然而,受限于耐药性,这些疗法也无法有效改善黑色素瘤患者的预后。因此,需要新的预后方法来指导个体化治疗和改善预后。本文利用TCPA和TCGA数据集的多因素COX分析,建立基于P21、YAP、X1433ZETA、CKIT、S6、CD20、LCK、P27、CD49B、GATA6和SRC_pY416蛋白质的预后模型。风险评分分析显示,风险评分高的患者预后较差。单因素和多因素COX模型分析显示预后与风险评分相关。共表达分析确定了与预后模型中蛋白质共表达的各种蛋白质。将低风险蛋白质GATA6和高风险蛋白质X1433ZETA在黑色素瘤细胞中过表达,GATA6抑制肿瘤生长,X1433ZETA促进肿瘤生长。本文所建立的黑色素瘤预后模型可潜在应用于个体化治疗指导。

Melanoma is one of the most aggressive and difficult to treat cancers.Currently,Melanoma is mainly treated by using targeted and immunotherapeutic agents.However,their success is limited by the development of resistance,which curtails long-term response rates.Thus,novel prognostic approaches are needed to guide individualized treatment and improve outcomes.In this paper,a multicox analysis of TCPA and TCGA datasets is used to develop a prognostic model based on P21,YAP,X1433ZETA,CKIT,S6,CD20,LCK,P27,CD49B,GATA6 and SRC_pY416 proteins.Risk score analysis for each patient indicated that those with high risk scores had worse prognosis relative to those with low risk scores.Cox and multi-Cox model analyses revealed that prognosis correlated with risk scores.Co-expression analysis identified various proteins that were co-expressed with the prognostic model’s proteins.Overexpression of the low risk protein,GATA6,and the high risk protein X1433ZETA,in melanoma cells revealed tumor growth suppression by GATA6,and tumor growth promotion by X1433ZETA,in vitro andin vivo.In conclusion,this novel melanoma prognostic model can guide individualized treatment.